Mentions
Extended reach
Total likes
Video views
AI synopsis
Several posts highlight the significant findings from the SUMMIT trial, such as a '38% reduction in HF events or CV death compared with placebo' and reports of clinical improvements in patient quality of life. The choice of words like 'excellent evidence' and phrases indicating 'huge win for HFpEF patients' show an optimistic tone, contributing to the overall positive sentiment towards tirzepatide's role in heart disease management.
Most discussions express a supportive view towards the findings and potential of tirzepatide, indicating a general agreement with the study results.
The discussions highlight strong curiosity regarding tirzepatide's efficacy in treating heart failure and obesity, reflecting a high level of interest in the implications of the findings.
While many posts reference the findings, few delve into detailed implications or criticisms, suggesting moderate engagement.
Participants generally foresee significant consequences of this research on clinical practice and patient outcomes, indicating that they believe the publication will have a noteworthy impact on the field.
In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Full trial results and Plain Language Summary: https://t.co/8joe2mst3e https://t.co/qbQdsrTw3m
Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening heart failure and improved health status in patients with #HFpEF and obesity. https://t.co/O9iU9a1Xgw https://t.co/4G47RRtYmB
Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst3e Editorial: Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction https://t.co/hpmbSDk76L #Cardiology https://t.co/OzUft2h4bB
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure than placebo and improved health status in patients with heart failure with https://t.co/ZsBNiU2Gfz
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity TOP TEN 2024 Treatment with tirzepatide led to a lower risk of a composite of death from Cv causes or worsening HF and improved health status in HFPEF and obesity https://t.co/fbvGLz6KbQ https://t.co/EPNrRB4FIx
60-Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Read the full trial results: https://t.co/8joe2mst3e @chrispan05 https://t.co/A36yQjGo6d
This podcast discusses the TAPIT STRIDE FreshUP and SINGLE SHOT CHAMPION trials, focusing on the effects of tirzepatide in heart failure management. The trials indicate that tirzepatide may lead to fewer cardiovascular…
Halle Tecco discusses her work connecting technology and healthcare, including a venture that allows women to freeze their eggs for free by donating. The video also addresses how obesity increases heart failure risk…
The SUMMIT trial tested tirzepatide in patients with obesity-related HFpEF and found a 38% reduction in HF events or CV death compared with placebo. Patients also reported clinically meaningful improvements in symptoms and quality of life. https://t.co/JvIibvmNyV
RT @EricTopol: Another GLP-1 drug success. Tirzepatide in heart failure with preserved ejection fraction (HFpEF) with longer term follow-up…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @BagaiDr: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine. death from cardi…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine. death from cardiovascular causes or worsening heart-failure event occurred in (9.9%) in tirzepatide & (15.3%) in placebo (HR, 0.62;P=0.026). https://t.co/dwQOUDkWO3
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/aSw091H2Kj
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure than placebo and improved health status in patients with heart failure with https://t.co/ZsBNiU2Gfz
@BandyGit @AllisonPearson @elonmusk https://t.co/3Ory5uzVec
RT @NEJM: 60-Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart fa…
RT @NEJM: 60-Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart fa…
RT @NEJM: 60-Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart fa…
RT @NEJM: 60-Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart fa…
RT @NEJM: 60-Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart fa…
60-Second Journal Club: The SUMMIT trial examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Read the full trial results: https://t.co/8joe2mst3e @chrispan05 https://t.co/A36yQjGo6d
BMI30以上のHFpEFにtirzepatide (マンジャロ)による治療はプラセボと比較して、心血管疾患による死亡または心不全の悪化の複合リスクを低減し、該当患者の状態を改善した Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine
RT @DrDamluji: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM
@BiotechObserver https://t.co/svn15pVEeb
RT @deepakdeepak: https://t.co/mDYmKsFHrF 58% more cardiovascular deaths with #tirzepatide or #mounjaro, and 25% more all cause deaths, bu…
RT @abdelhamed012: Tirzepatide decreased CVD (HR 0.62) and quality of life in HFpEF+obesity in SUMMIT; baseline eGFR 56, 58% CKD3, 33% albu…
"Conclusions: Treatment with tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure"
Tirzepatide decreased CVD (HR 0.62) and quality of life in HFpEF+obesity in SUMMIT; baseline eGFR 56, 58% CKD3, 33% albuminuria) Tirzepatide lowered SBP -5mmHg, blood vol, CRP 37%, ACR 25%, ntproBNP 11%. Increased eGFR 2.9 at 52wks w/slight initial dip https://t.co/BHz5fYyWFe
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity TOP TEN 2024 Treatment with tirzepatide led…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity TOP TEN 2024 Treatment with tirzepatide led…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity TOP TEN 2024 Treatment with tirzepatide led…
Tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure than placebo in HFpEF and obesity. nejm https://t.co/LCRmBF3jhq
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity TOP TEN 2024 Treatment with tirzepatide led…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity TOP TEN 2024 Treatment with tirzepatide led…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity TOP TEN 2024 Treatment with tirzepatide led…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity TOP TEN 2024 Treatment with tirzepatide led to a lower risk of a composite of death from Cv causes or worsening HF and improved health status in HFPEF and obesity https://t.co/fbvGLz6KbQ https://t.co/EPNrRB4FIx
RT @Basalus: 4/ SUMMIT: Tirzepatide in HFpEF & obesity improved CV death/worsening HF events (HR 0.62, p=0.026) and KCCQ-CSS score (p<0.001…
4/ SUMMIT: Tirzepatide in HFpEF & obesity improved CV death/worsening HF events (HR 0.62, p=0.026) and KCCQ-CSS score (p<0.001). Another win for GLP-1s in HF?
RT @IGOARANBAR: @tatana2007 @redGDPS @carlos_teixi @AntonietaVidalT @DGLopez8 @cornejo_79 @fcbzafra @NadiamadridIII @FatimaVillaf @anicebri…
@tatana2007 @redGDPS @carlos_teixi @AntonietaVidalT @DGLopez8 @cornejo_79 @fcbzafra @NadiamadridIII @FatimaVillaf @anicebrian @FranAdanGil @MBelenBenito #Tirzepatida demostró reducción del "combinado de reducción de MCV O empeoramiento de IC". Con esta sutil diferencia, O no es Y, habrá que analizar más en profundidad los datos de este y otros estudios tanto con #semaglutida como con tirze. https://t.co/ODfMCqxOq4 https://t.co/y253SeR58u
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity https://t.co/Rv1bPBKDaT
Tirzepatide shows promise for heart failure with preserved ejection fraction (EF≥50%) & obesity in 731 patients, offering significant weight loss and potential CV benefits. #HeartHealth PMID:39555826, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2410027
(BMJ) Diagnóstico y tto del sarampión https://t.co/uuwKWJNe8u Revisión https://t.co/wi4PlrVDib
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @deepakdeepak: https://t.co/mDYmKsFHrF 58% more cardiovascular deaths with #tirzepatide or #mounjaro, and 25% more all cause deaths, bu…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
Tirzepatide reduced cardiovascular events and improved health status in obese patients with heart failure and preserved ejection fraction. by Packer M, Zile MR (...) Borlaug BA et 10 al. in N Engl J Med #MedSky
Tirzepatide reduced cardiovascular events and improved health status in obese patients with heart failure and preserved ejection fraction. by Packer M, Zile MR (...) Borlaug BA et 10 al. in N Engl J Med https://t.co/qGs9msoxYm #MedX #MedResearch
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/LayBOprWKF
RT @Saludteca: Tirzepatida para la insuficiencia cardiaca en pacientes con obesidad https://t.co/MadwEeJCvv
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
Tirzepatida para la insuficiencia cardiaca en pacientes con obesidad https://t.co/MadwEeJCvv
Tirzepatida para la insuficiencia cardiaca con fracción de eyección preservada y obesidad https://t.co/x2JpUs57eb PMID 39555826
【DrゆみのWeekly Journal Scan】 ＊肥満合併心不全患者へのGLP1受容体作動薬 from NEJM＊ https://t.co/n7VFrLXb9F
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
RT @scottisaacsmd: Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening hea…
Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening heart failure and improved health status in patients with #HFpEF and obesity. https://t.co/O9iU9a1Xgw https://t.co/4G47RRtYmB
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/TyXgR1o2pd
A lot of discussion about GLP1 drugs at Anesthesia Camp Grand Cayman. This new study suggests benefits. Heart failure in obese patients. More full stomachs coming your way? https://t.co/ZYdGjdm1Qq It cut the combination of death and worsened heart failure from 15% to 10%. https://t.co/sx66U2RMtg
A lot of discussion about GLP1 drugs at Anesthesia Camp Grand Cayman. This new study suggests benefits. Heart failure in obese patients. More full stomachs coming your way? https://t.co/FGD4EhEFs7 It cut the combination of death and worsened heart failure from 15% to 10%. https://t.co/esL0WToYiP
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @RosaCasan: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/wP…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/wP6j0FqjgK
RT @ObesitySeen: Tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure and improved…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @ObesitySeen: Tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure and improved…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
RT @NEJM: In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure wi…
In the SUMMIT trial, researchers examined cardiovascular outcomes of treatment with tirzepatide in patients with heart failure with preserved ejection fraction and obesity. Full trial results and Plain Language Summary: https://t.co/8joe2mst3e https://t.co/qbQdsrTw3m
Tirzepatide shows promise for heart failure with preserved ejection fraction (EF≥50%) & obesity in 731 patients, offering significant weight loss and potential CV benefits. #HeartHealth PMID:39555826, N Engl J Med 2025, @NEJM https://t.co/kTw0ertxM9
ほんとかな Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/OgFVZGpm78
RT @deepakdeepak: https://t.co/mDYmKsFHrF 58% more cardiovascular deaths with #tirzepatide or #mounjaro, and 25% more all cause deaths, bu…
https://t.co/mDYmKsFHrF 58% more cardiovascular deaths with #tirzepatide or #mounjaro, and 25% more all cause deaths, but yet the drug is considered a "Huge Win for HFpEF Patients with Obesity." #HFpEF is heart failure with preserved ejection fraction.This trial is on HFpEF https://t.co/RRg7ZaldH9
https://t.co/mDYmKsFHrF 58% more cardiovascular deaths with #tirzepatide or #mounjaro, and 25% more all cause deaths, but yet the drug is considered a "Huge Win for HFpEF Patients with Obesity." #HFpEF is heart failure with preserved ejection fraction.This trial is on HFpEF https://t.co/YQaZbHhP2j
RT @ObesitySeen: Tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure and improved…
RT @ObesitySeen: Tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure and improved…
RT @kamleshkhunti: Tirzepatide for heart failure with preserved ejection fraction in people living with obesity ⬇️ risk of a composite of…
RT @ObesitySeen: Tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure and improved…
RT @ObesitySeen: Tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure and improved…
Tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure and improved health status in patients with heart failure with preserved ejection fraction and obesity. https://t.co/IRPa4owxt4 @seen @seedo @NEJM
Ignore all the weight loss stuff. Now will insurance cover this “heart failure drug” called tirzepatide?
Tirzepatide (Mounjaro) for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/pWcA2xOOWL
RT @kamleshkhunti: Tirzepatide for heart failure with preserved ejection fraction in people living with obesity ⬇️ risk of a composite of…
RT @kamleshkhunti: Tirzepatide for heart failure with preserved ejection fraction in people living with obesity ⬇️ risk of a composite of…
RT @kamleshkhunti: Tirzepatide for heart failure with preserved ejection fraction in people living with obesity ⬇️ risk of a composite of…
RT @kamleshkhunti: Tirzepatide for heart failure with preserved ejection fraction in people living with obesity ⬇️ risk of a composite of…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/FVBZiwmnDI
Link: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/NFtkFRBx69
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity https://t.co/Wdnfpw2B3g
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
Excellent new evidence for treating #HFpEF (with BMI>30) using #Trizepatide #summit @NEJM reduces combined risk of CV mortality and worsening #HF by 38% and reduces risk of worsening #HF events by 46% @BSHeartFailure #CardioTwitter https://t.co/gM7tms1owb
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/tlFtfM4XF2
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity https://t.co/amk4P5Q2Gq
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
“Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.” Étude SUMMIT. Publiée ce jour dans le @nejm.org. #Medsky #Cardiology www.nejm.org/doi/full/10....
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/9gutJAJPaO
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. www.nejm.org/doi/full/10.... @nejm.org #CardioSky #MedSky #Cardiology #GLP1 #HeartFailure #Tirzepatide #Obesity #HFpEF
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
RT @NEJM: Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst…
Original Article: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT trial) https://t.co/8joe2mst3e Editorial: Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction https://t.co/hpmbSDk76L #Cardiology https://t.co/OzUft2h4bB
I also presented the SUMMIT-Trial entitled “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity” ⬇️ https://t.co/HtSjzeE64u
SCVC Journal club. 竹内先生が肥満のHFpEF症例に対するTirzepatideの効果を検討したRCT論文を紹介‼️ SCVC Journal club. Dr. Takeuchi presents the following paper: https://t.co/39fcW5Ta2N @Laserrman @SCVC2023 @tsuyokappa @scvc_kensa https://t.co/5XZF95DipC
Full Abstract links https://t.co/uhPX3T2FwD https://t.co/0lUVaXHPvR
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity https://t.co/KdlmxV3OCc
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity tirzepatide led to a lower risk of a compos…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity tirzepatide led to a lower risk of a composite of death from cardiovascular causes or worsening heart failure than placebo and improved health status in HFPEF and obesity https://t.co/t3lJM4yp6U https://t.co/oaUteo0xoP
RT @Obesidades_mx: @ConscienHealth -Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N…
@ConscienHealth -Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. -Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2024.
2024 best publication in heart failure Grand prix 2024 Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to lower risk of a composite of death from cardiovascular causes or worsening HF https://t.co/t3lJM4xRhm https://t.co/XkCM7Rk7LE
7/14 Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity... https://t.co/LSSuGNqYZs
RT @DrAkhilX: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity https://t.co/L4fqVLQvJ2 https://t.co/B1PmM3cF4B
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity 5 https://t.co/Eo06eEzF4U
RT @DrAkhilX: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity https://t.co/L4fqVLQvJ2 https://t.co/B1PmM3cF4B
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity https://t.co/L4fqVLQvJ2 https://t.co/B1PmM3cF4B
RT @cardio_tu: 2 min cardiology（臨床、担当：白戸崇） Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Milton Packer et a…
2 min cardiology（臨床、担当：白戸崇） Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Milton Packer et al. NEJM Nov 16, 2024 https://t.co/mFAD4tbvGR →
肥満pEF症例にチルゼパチドも同様の結果。 https://t.co/QLP7pBj4OC
チルゼパチド（GLP-1, GIPデュアルアゴニスト）の心疾患、肥満の予防効果を調べたNEJMの論文 ☑︎ 心不全の悪化はHR：0.54とチルゼパチドで減少したが、心血管系の死亡は8例 vs 5例（N=364）とややチルゼパチド群が高かった（プラセボコントロール） https://t.co/OxyeouaI4B
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/JGaLaLPZy6
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/BaF8R0RixY De nuevo otro fármaco que disminuye la obesidad disminuye los eventos relacionados con ICC, pero no la mortalidad per se.
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
RT @drbennisahmed: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower ri…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Treatment with tirzepatide led to a lower risk of a composite of death from CV causes or WHF than placebo and improved health status in patients with HFPEF and obesity https://t.co/t3lJM4xRhm https://t.co/wq445vUhgs
RT @DrDamluji: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM
Tirzepatide significantly reduced cardiovascular risks and improved health status in obese heart failure patients compared to placebo. by Packer M, Zile MR (...) Borlaug BA et 10 al. in N Engl J Med https://t.co/GT3gZdj6yn
RT @almucastro01: #LaSECteLleva a conocer el estudio SUMMIT: ( Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity )…
【RCT】BMI30以上かつ駆出率50%以上の心不全患者へのチルゼパチドの投与は、プラセボの投与と比較して、心血管死亡または心不全悪化イベントリスクを減少させた。KCCQ-CSSを改善させた。 #ペ読 https://t.co/SgNqcKx57N
#LaSECteLleva a conocer el estudio SUMMIT: ( Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity ) Excelente resumen de @david_gv https://t.co/bzwyE61peC Accede con tus claves y si no las tienes aún, regístrate gratis. https://t.co/X5yVp6MljV
RT @venumenon10: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine: kudos to the…
Trend top+1: Packer M, ..., Summit Trial Study Group (N Engl J Med) __Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity__ https://t.co/Gdca8zjj98
RT @MohammedAlo: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Tirzepatide is a dual agonist of GIP and GLP-1…
RT @MohammedAlo: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Tirzepatide is a dual agonist of GIP and GLP-1…
RT @MohammedAlo: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Tirzepatide is a dual agonist of GIP and GLP-1…
The next step in HFPEF patients with obesity Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity | New England Journal of Medicine https://t.co/UvZLo4eyd2
RT @DrDamluji: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM
RT @DrDamluji: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM
RT @MohammedAlo: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Tirzepatide is a dual agonist of GIP and GLP-1…
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Tirzepatide is a dual agonist of GIP and GLP-1 receptors.
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity - SUMMIT trial. Bravo @clevelandclinic.bsky.social Cardiology! www.nejm.org/doi/full/10....